Table 4.
Variable | LRC | PFS | OS | CSS | ||||
---|---|---|---|---|---|---|---|---|
Hazard Ratio (95% CI) |
p Value | Hazard Ratio (95% CI) |
p Value | Hazard Ratio (95% CI) |
p Value | Hazard Ratio (95% CI) |
p Value | |
Age (per year) | 1.04 (0.98–1.12) |
0.23 | 1.00 (0.97–1.03) |
0.88 | 1.01 (0.98–1.04) |
0.55 | 1.0 (0.96–1.05) |
0.85 |
T stage: u/cT3-4 (74) vs. u/cT1-2 (16) |
0.88 (1.87–4.16) |
0.87 | 1.36 (0.57–3.22) |
0.49 | 1.89 (0.67–5.31) |
0.23 | 0.93 (0.31–2.76) |
0.89 |
cN stage: cN+ (75) vs. cN0 (15) | 1.69 (0.21–13.39) |
0.62 | 0.92 (0.41–2.08) |
0.85 | 0.87 (0.38–1.97) |
0.74 | 0.46 (0.18–1.19) |
0.11 |
Chemotherapy | ||||||||
Carboplatin/paclitaxel (27) vs. 5-fluorouracil/cisplatin (63) |
2.19 (0.59–8.18) |
0.24 | 0.73 (0.35–1.54) |
0.41 | 0.76 (0.35–1.68) |
0.50 | 0.50 (0.01–1.71) |
0.27 |
Chemotherapy complete: yes (66) vs. no (24) |
1.46 (0.38–5.69) |
0.58 | 1.49 (0.78–2.86) |
0.23 | 1.49 (0.76–2.95) |
0.25 | 1.73 (0.69–4.31) |
0.24 |
pCR: yes (35) vs. no (55) | 0.08 (0.01–0.66) |
0.02 | 0.25 (0.13–0.50) |
<0.01 | 0.19 (0.08–0.42) |
<0.01 | 0.14 (0.04–0.48) |
<0.01 |
Acute organ toxicity ≥ III°: yes (26) vs. no (64) |
2.43 (0.68–8.71) |
0.17 | 1.94 (1.06–3.56) |
0.03 | 1.78 (0.93–3.42) |
0.08 | 2.58 (1.08–6.15) |
0.03 |
Maximal dysphagia ≥ III° during RCT: yes (29) vs. no (61) |
2.75 (0.79–9.64) |
0.11 | 1.67 (0.91–3.04) |
0.09 | 1.36 (0.71–2.63) |
0.35 | 3.47 (1.45–8.29) |
<0.01 |
Acute hematologic/organ toxicity ≥ III°: yes (38) vs. no (52) |
1.30 (0.37–4.64) |
0.69 | 1.54 (0.86–2.76) |
0.15 | 1.52 (0.82–2.85) |
0.19 | 2.58 (1.06–6.13) |
0.03 |
ICU/IMC stay: ≥7 (31) vs. ≤6 (50) days |
1.34 (0.36–4.99) |
0.67 | 1.87 (1.01–3.49) |
<0.05 | 1.78 (0.93–3.39) |
0.08 | 2.56 (1.05–6.28) |
0.04 |